Ethic Inc. Acquires 2,966 Shares of argenex SE $ARGX

Ethic Inc. increased its holdings in shares of argenex SE (NASDAQ:ARGX) by 265.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 4,085 shares of the company’s stock after buying an additional 2,966 shares during the period. Ethic Inc.’s holdings in argenex were worth $3,435,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ARGX. AQR Capital Management LLC boosted its stake in shares of argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after purchasing an additional 122 shares in the last quarter. NewEdge Advisors LLC raised its position in shares of argenex by 5,962.5% in the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after acquiring an additional 1,431 shares in the last quarter. Focus Partners Wealth raised its position in shares of argenex by 22.3% in the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after acquiring an additional 73 shares in the last quarter. Geneos Wealth Management Inc. raised its position in shares of argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after acquiring an additional 99 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of argenex by 60.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock worth $73,000 after acquiring an additional 50 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenex Stock Performance

Shares of NASDAQ ARGX opened at $813.28 on Tuesday. The company has a market cap of $50.58 billion, a PE ratio of 36.21, a P/E/G ratio of 1.31 and a beta of 0.46. The business has a 50-day simple moving average of $755.99 and a two-hundred day simple moving average of $816.91. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. The business had revenue of $1.31 billion during the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%. On average, sell-side analysts predict that argenex SE will post 23.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ARGX shares. Guggenheim boosted their price target on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research report on Friday. Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Wall Street Zen cut shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. HC Wainwright raised their price target on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Citizens Jmp raised their price target on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a report on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,017.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.